← Back to Search

Immunosuppressant

Chemotherapy + Stem Cell Transplant for Cancer

Phase 1

Waitlist Available

Research Sponsored by Milton S. Hershey Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status (PS) 0-2 OR Lansky PS 70-100%

Relapsed or refractory disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is giving chemotherapy to young patients with cancer before transplanting stem cells from an umbilical cord in order to stop the growth of tumor cells and help the patient's immune system accept the new stem cells.

Who is the study for?

This trial is for young patients with solid tumors that have come back or didn't respond to treatment. They should not have just a local recurrence over a year after therapy, must have an unrelated cord blood donor, and meet specific health criteria like good heart function and kidney clearance.Check my eligibility

What is being tested?

The study tests if chemotherapy drugs (busulfan, melphalan) and antithymocyte globulin followed by umbilical cord blood transplant can help treat these tumors. It aims to see how well the body tolerates this approach and if it helps fight the cancer.See study design

What are the potential side effects?

Possible side effects include reactions to the immune system suppressants, impact on organ functions from chemotherapy, risk of infection due to immune suppression, and potential graft-versus-host disease where transplanted cells attack the patient's own cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can care for myself and am up and about more than 50% of my waking hours.

Select...

My condition has returned or didn't respond to treatment.

Select...

I have been diagnosed with a solid tumor cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of graft-versus-host disease

Safety

Secondary outcome measures

Donor/host chimerism status

Immune function post-transplant

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor

492 Previous Clinical Trials

2,798,802 Total Patients Enrolled

Kenneth G. Lucas, MDStudy ChairMilton S. Hershey Medical Center

9 Previous Clinical Trials

87 Total Patients Enrolled

Media Library

Antithymocyte Globulin (Immunosuppressant) Clinical Trial Eligibility Overview. Trial Name: NCT00436761 — Phase 1

Solid Tumors Clinical Trial 2023: Antithymocyte Globulin Highlights & Side Effects. Trial Name: NCT00436761 — Phase 1

Antithymocyte Globulin (Immunosuppressant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00436761 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapy been accepted by the Federal Drug Administration?

"With limited safety and efficacy data, our team has assigned a score of 1 to this treatment. As it is currently in Phase 1 trials, the study's primary focus is on assessing its potential risks and benefits."

Answered by AI

Are there currently any openings for participants in this clinical trial?

"As per clinicaltrials.gov, this research is no longer in need of subjects; the trial was posted on May 1st 2004 and had its last update on December 17th 2013. Nonetheless, there are 2,380 other trials that remain open for recruitment currently."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

2004. "Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00436761.

All > Restasis